Corpus ID: 169589817

Hepatitis autoinmune: etiopatogenia, diagnóstico y tratamiento

  title={Hepatitis autoinmune: etiopatogenia, diagn{\'o}stico y tratamiento},
  author={B. B. Rodr{\'i}guez and Mar{\'i}a Jos{\'e} Rodr{\'i}guez Sicilia and J. Mor{\'o}n},
Resumen La hepatitis autoinmune es una enfermedad de curso insidioso que se defi ne como la infl amacion cronica del parenquima hepatico de etiologia desconocida. En su etiopatogenia parecen infl uir desencadenantes medioambientales y falta de tolerancia en pacientes geneticamente predispuestos que conllevan el ataque del parenquima hepatico por parte de linfocitos T. Para su diagnostico se requieren caracteristicas histologicas y analiticas especifi cas, entre las que destacan… Expand
Hepatitis autoinmune en un paciente con hepatitis B crónica, a propósito de un caso
There are few reports in the literature that describe the possibility of finding viral hepatitis and autoimmune hepatitis in one patient at the same time, and some studies have indicated that there is possible correlation between them. Expand
Evolución de cirrosis biliar primaria a síndrome de solapamiento con hepatitis autoinmune en paciente con hepatitis B crónica
Se realiza una revision sobre the entidad clinica del sindrome de solapamiento CBP-HAI y las caracteristicas especiales de esta paciente para alcanzar el diagnostico y su tratamiente. Expand


Autoimmune hepatitis: clinical challenges.
AIH is a chronic, mainly periportal hepatitis associated with hypergammaglobulinemia and circulating autoantibodies, which, in most cases, responds to immunosuppressive treatment and frequently overlaps with other autoimmune liver diseases that affect the biliary tract. Expand
Understanding the pathogenesis of autoimmune hepatitis
  • A. Czaja
  • Medicine
  • American Journal of Gastroenterology
  • 2001
The pathogenic mechanisms of autoimmune hepatitis are reviewed, gaps in knowledge are identified, and future investigative efforts are focused on individual determinants of autoantigen presentation, immunocyte activation, and liver cell destruction. Expand
Simplified criteria for the diagnosis of autoimmune hepatitis
A reliable diagnosis of AIH can be made using a very simple diagnostic score proposed, which is the diagnosis of probable AIH at a cutoff point greater than 6 points and definite AIH 7 points or higher. Expand
Treatment challenges and investigational opportunities in autoimmune hepatitis
New drugs and advances in molecular biology afford opportunities to upgrade the treatment of autoimmune hepatitis. The aims of this study were to define treatment problems, identify possibleExpand
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.
Treatment with UDCA alone normalizes the survival rate of patients with PBC when given at early stages, and there is a continued need for new therapeutic options in patients with advanced disease. Expand
Anti-LC1 autoantibodies in patients with chronic hepatitis C virus infection.
Anti-LC1 autoantibodies can be regarded as a serological marker of autoimmunity in chronic hepatitis C infection in patients infected with hepatitis C virus and their production is not dependent of anti-LKM1 auto Antibodies formation. Expand
Current and novel immunosuppressive therapy for autoimmune hepatitis
Current management strategies of AIH are examined, available data pertaining to the use of novel immunosuppressive agents in this condition are evaluated, and alternative strategies in patients who have failed to achieve remission on “standard therapy” of corticosteroids with or without azathioprine or patients with drug toxicity are evaluated. Expand
Diagnosis and treatment of autoimmune hepatitis
These guidelines provide a data-supported approach to the diagnosis and management of patients with autoimmune hepatitis and modified the categories of the Infectious Diseases Society of America’s Quality Standards to standardize recommendations. Expand
Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end‐stage liver disease
Onset at an early age, acute presentation, hyperbilirubinemia, and presence of HLA DRB1*03 characterize patients who fail corticosteroid treatment, suggesting the model for end‐stage liver disease may be a useful instrument for identifying patients prone to this outcome. Expand
Genetics in autoimmune hepatitis.
Type 1 AIH studies have focused on the major histocompatibility complex (MHC), mapping susceptibility to the DRB1 region, and studies outside the MHC have identified the CTLA4 A+49G, G allele as a possible second risk allele. Expand